ASCELIA PHARMA

ADVANCING ORPHAN ONCOLOGY

PRESENTATION AT ABGSC LIFE SCIENCE SUMMIT 26 MAY 2020



Share ticker: ACE Nasdaq Stockholm (small cap)

ASCELIA PHARMA: ADVANCING ORPHAN ONCOLOGY

A global health burden

44 million people live with cancer; 18 million are diagnosed each year¹

USD 150 bn spent yearly on cancer therapies alone²

Orphan drugs represent 12 of 15 new active substances in oncology launched in the US in 2018²

Dedicated to unmet needs in orphan oncology

Drugs with a clear development and market pathway

- Advancing liver imaging with orphan MRI contrast agent with no competition (in ongoing Phase 3)
- Advancing chemotherapy with novel tablet for gastric cancer (Phase 2 ready)

Capabilities to bring new compounds to market


- World class cross-functional team
- Headquartered in Malmö, Sweden
- Listed on NASDAQ STOCKHOLM in 2019 (ticker: ACE)
- Solid financial position with SEK 169 million in liquid assets



Sources
1) https://canceratlas.cancer.org/the-burden/the-burden-of-cancer/ (2018 figures)
2) Clabel Oracles Transfe 2019 (2) (4/2019 figures)

2) Global Oncology Trends 2019, IQVIA (2018 figures)

CLINICAL STAGE PORTFOLIO ADDRESSING CLEAR UNMET NEEDS





MANGORAL

LIVER MRI CONTRAST AGENT IN PHASE 3 CLINICAL STUDIES

LIVER METASTASES – A MAJOR CHALLENGE IN ONCOLOGY

LIVER METASTASES COMMON IN MANY CANCER TYPES

The liver is the **most frequent** organ for metastases after lymph node³ and often the first site of metastasis

- 70% of patients with colon cancer will develop liver metastases¹
- Liver metastases are also common in other cancer types such as lung cancer, gastric cancer, metastatic breast cancer^{2,3} etc.


Liver metastases often the **cause of mortality** (not primary tumour)⁴



Riihimäki, M. et al. Patterns of metastasis in colon and rectal cancer. Sci. Rep. 6, 29765; doi: 10.1038/srep29765 (2016); Journal of Pathology, 2014, 232:23-31

- 2) Oncotarget, 2016, 7(32):52307; Lung Cancer, 2014, 86:78-84 (6):29765
- 3) Guy diSibio and Samuel W. French (2008) Metastatic Patterns of Cancers: Results From a Large Autopsy Study. Archives of Pathology & Laboratory Medicine: June 2008, Vol. 132, No. 6, pp. 931-939
- 4) Rahbari et al. Metastatic Spread Emerging From Liver Metastases of Colorectal Cancer: Does the Seed Leave the Soil Again? Annals of Surgery: February 2016 Volume 263 Issue 2 p 345-352

Incidence of liver metastasis in various primary cancers ¹⁻⁴



* Metastatic breast cancer



LIVER METASTASES: HOW TO FIND AND WHAT TO DO

DETECT AND LOCALISE

Liver MRI is the **most sensitive** method for detection of liver metastases²⁾

Gadolinium based imaging drugs are given to maximise accuracy of liver metastasis detection in MRI




TREAT

Treatment options for liver metastases are:

- Surgical resection (only if detected early)
- Localised therapies (ablation embolisation, radiation)
- Drug therapy

IMPROVE SURVIVAL


Accurate, early detection of liver metastases significantly impact treatment decisions and <u>patient survival</u>






1) Guy diSibio and Samuel W. French (2008) Metastatic Patterns of Cancers: Results From a Large Autopsy Study. Archives of Pathology & Laboratory Medicine: June 2008, Vol. 132, No. 6, pp. 931-939 2) Albiin N et al. Manganese chloride tetrahydrate (CMC-001) enhanced liver MRI: evaluation of efficacy and safety in healthy volunteers. MAGMA. 2012 Mar 8 3) Clinical Colorectal Cancer, Vol. 15, No. 4, Dec 2016, e183-192

MANGORAL – MANGANESE BASED LIVER CONTRAST AGENT




MANGORAL MAKES A REAL DIFFERENCE

PATIENT EXAMPLE FROM PHASE II STUDY



Unenhanced liver MRI

(standard of care today in target patient population)



Mangoral enhanced liver MRI

Liver metastasis appear with Mangoral

MANGORAL CLINICAL ACTIVITES

Study	Objective of the study	Site location and no. of patients	Time schedule
Pivotal Phase 3 study ("SPARKLE")	Assess efficacy and safety of Mangoral in patients with severely reduced kidney function and with known or suspected liver lesions	Global multicentre study in up to 200 patients	 Study ongoing Study results expected in H2-2021
Hepatic study	Assess the influence of hepatic impairment on the safety, pharmacokinetics and pharmaco- dynamics of Mangoral	Open-label study on 24 healthy and hepatically impaired participants at the Texas Liver Institute, San Antonio, US	Study ongoingStudy expected to be completed in 2020
Food effect study	Assess the effect of food intake on Mangoral uptake	Study contract to be awarded	 Study preparations ongoing Short study, expected to be completed in 2020

These studies, together with the already completed Phase 1 and 2 studies, ensure a comprehensive data package for the regulatory submissions in key markets



DE-RISKED PHASE 3 STUDY UNDERPINNED BY STRONG DATA FROM COMPLETED STUDIES AND STUDY DESIGN


Phase 3 registration-enabling study (study ongoing) Strong data package for Mangoral Six phase 1 and 2 clinical studies completed Consistent strong efficacy readout and safety profile Blind read study of all imaging data presented at major conferences The study with 178 persons further underlined that Mangoral significantly improves MRI performance 33% more lesions were detected after Mangoral enhanced MRI Mangoral significantly improved lesion visualisation Delineation: p-value < 0.0001 Conspicuity: p-value < 0.0001

Number Global study in up to 200 patients of patients Endpoint Lesion visualisation • Lesion border delineation (border sharpness of lesions) • Conspicuity (lesion contrast compared to liver background) **Comparator** Unenhanced MRI + Mangoral MRI VS. Unenhanced MRI **Follow-up** 72 hours 12 Randomisation No - each patient at his/her own control m Validation Phase 3 program has been discussed with) E FDA and EMA



MANGORAL IS THE ONLY PRODUCT IN A \$350-500M MARKET

Addressable market





OUTLOOK FOR MARKET OPTIMAL LAUNCH STRATEGY

Strong case for own US commercialisation

US operations

- Field team of 10-20 FTEs can target 3,500-5,000 key accounts
- Target major hospitals with nephrology departments and independent specialist clinics
- US capability to include commercial and cross-functional support team

Optimal RoW uptake with partnering

Europe, Japan and RoW

- Market roll-out according to market potential, pricing and access
- Leverage global synergies in pre-launch and launch
- Ascelia vs. partner roles evaluated to maximise value



ADVANCING ORAL CHEMOTHERAPY

13

ONCORAL

CHEMOTHERAPY TABLET FOR GASTRIC CANCER READY FOR PHASE 2

ONCORAL – NOVEL IRINOTECAN TABLET READY FOR PHASE 2

NOVEL ORAL PATENTED FORMULATION



Formulated as a **tablet** for convenient dosing and healtheconomic benefits



Promising safety potential of oral administration





Irinotecan shown to be effective in killing cancer cells

	 ✓ — ■
	 ✓ — ■
	~ — I
	V —
_ 1	

Expected to be efficacious and safe together with other well-recognized anti-cancer drugs



Potential for **all-tablet chemo**combination



Orphan drug indication for gastric cancer by the FDA and EMA

With promising Phase 1 results, we are now preparing for Phase 2



PRIORITIES 2020 AND INVESTMENT HIGHLIGHTS



Priorities in 2020



First patient in the Phase 3 SPARKLE study



First participant in the hepatic study

Work diligently with study sites during Covid-19 and enrol additional patients

Pre-launch activities and preparations for Mangoral (market launch planned for Q4 2022 – H1 2023)

Prepare Phase 2 study for Oncoral (planned start in 2021)



INVESTMENT HIGHLIGHTS

Ascelia Pharma (ticker: ACE) – Advancing orphan oncology

- Drugs targeting unmet medical needs with known mode of action and low development risk
- Solid financial position: SEK 169 million in liquid assets per 31 Mar 2020

Mangoral – Phase 3 non-gadolinium liver imaging drug

- \$350-500 million annual addressable market
- No competing drugs
- Ongoing Phase 3 program with high likelihood of success study results expected in H2 2021

17

Orphan Drug Designation

Oncoral – Phase 2 ready oral chemotherapy for gastric cancer

- Novel tablet formulation with significant patient and hospital benefits
- Effective molecule for killing cancer
- Promising Phase 1 results and preparing for Phase 2

ASCELIA PHARMA

ascelia.com